JOURNAL ARTICLE

Severe myelosuppression involving HPV‐B19 infection and NUDT15 polymorphisms during therapy for LCH.

  • Published In: Pediatrics International, 2023, v. 65, n. 1. P. 1 1 of 3

  • Database: Academic Search Ultimate 2 of 3

  • Authored By: Hosokawa, Hiroki; Kitazawa, Hironobu; Akita, Nobuhiro; Yoshida, Nao; Hama, Asahito 3 of 3

Abstract

The article presents a case study of a seven-year-old boy with Langerhans cell histiocytosis (LCH) who experienced severe myelosuppression during chemotherapy with oral 6-mercaptopurine (6-MP). Topics discussed include the association of NUDT15 polymorphisms with fatal myelosuppression, the risk of human parvovirus B19 (HPV-B19) infection during myelosuppression, and the recommendation for genotyping NUDT15 before initiating thiopurine-containing therapy to avoid excess toxicity.

Additional Information

  • Source:Pediatrics International. 2023/01, Vol. 65, Issue 1, p1
  • Document Type:Case Study
  • Subject Area:Consumer Health
  • Publication Date:2023
  • ISSN:1328-8067
  • DOI:10.1111/ped.15669
  • Accession Number:174473887

Looking to go deeper into this topic? Look for more articles on EBSCOhost.